In our previous work, we targeted the key downstream regulatory gene mTOR of DNMT3A mutation with the mTOR inhibitor rapamycin, which significantly inhibited the proliferation of DNMT3A-mutated AML cell lines and prolonged the survival of Dnmt3a R878H AML mice [11]. This evidence concerns the gene MTOR and acute myeloid leukemia.